Business Context and Reporting Period
QuidelOrtho Corporation filed a Form 8-K dated September 23, 2026, reporting an amendment to its existing credit agreement originally dated August 21, 2025. The amendment was entered into with Bank of America, N.A., and the participating lenders. The filing does not report operating results for a fiscal period.
Financial Position and Key Metrics
- Financing facilities: $1.15 billion Term Loan A, $100.0 million delayed-draw Term Loan A, $1.45 billion Term Loan B, and a $700.0 million revolving credit facility.
- Security and guarantees: The facilities remain guaranteed by certain material domestic subsidiaries and secured by substantially all assets of the Company and guarantors, excluding real property and certain other excluded assets.
- Interest rates: During the covenant relief period, initial rates for the Term Loan A facilities and revolving facility are 1.50% per annum for base-rate loans and 2.50% per annum for Term SOFR loans, until the first business day after delivery of the compliance certificate for the fiscal quarter ending September 28, 2026. Thereafter, rates will be based on leverage and range from 1.75% to 3.00% for Term SOFR loans and 0.75% to 2.00% for base-rate loans.
- Revolving commitment fee: 0.20% to 0.40% per annum on the unused portion, based on the Company’s Consolidated Leverage Ratio.
- Term Loan B pricing: Unchanged by the amendment.
- Revenue, profit, cash flow, margins, and liquidity: The filing text does not provide clear values for these metrics or disclose revolver borrowings and cash balances.
Material Changes Versus the Prior Agreement
The amendment resets the Company’s financial covenant levels through the fiscal quarter ending September 30, 2029, creating a covenant relief period. It also adds certain financial restrictions during that period and establishes leverage-based interest-rate and commitment-fee pricing for specified facilities.
| Measurement period | Minimum interest coverage ratio | Maximum leverage ratio |
|---|---|---|
| On or prior to July 2, 2028 | 2.25 to 1.00 | 5.50 to 1.00 |
| October 1, 2028 or December 31, 2028 | 2.50 to 1.00 | 5.00 to 1.00 |
| April 1, 2029 or July 1, 2029 | 2.75 to 1.00 | 4.50 to 1.00 |
| On or after September 30, 2029 | 3.00 to 1.00 | 4.25 to 1.00 |
Outlook, Risks, Contingencies, and Unusual Items
- The stepped covenant thresholds provide temporary relief but require progressively stronger interest coverage and lower leverage beginning in 2028 and continuing through September 2029.
- The Credit Agreement retains customary affirmative and negative covenants, including restrictions on asset sales, mergers, indebtedness, liens, investments, restricted payments, certain debt prepayments, and affiliate transactions.
- Additional restrictions apply during the covenant relief period.
- The principal risk highlighted by the filing is compliance with the revised leverage and interest coverage requirements while the Company remains subject to substantial secured debt.
- The filing does not provide management guidance, operating forecasts, liquidity projections, or information regarding covenant compliance as of the filing date.
Important Facts for Investors to Verify
- Review Exhibit 10.1 for the complete amendment terms, definitions, conditions, and additional restrictions.
- Confirm outstanding balances, scheduled maturities, amortization, and availability under each financing facility.
- Assess the Company’s current and projected Consolidated Leverage Ratio and Consolidated Interest Coverage Ratio against the revised thresholds.
- Verify the first applicable interest-rate pricing period after delivery of the September 28, 2026 compliance certificate.
- Review subsequent filings for actual operating performance, liquidity, borrowing levels, and compliance with the amended covenants.